# Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab

> **NCT06003998** · PHASE2 · UNKNOWN · sponsor: **Catharina Ziekenhuis Eindhoven** · enrollment: 85 (estimated)

## Conditions studied

- Colorectal Cancer
- Peritoneal Metastases

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** FOLFOX regimen
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06003998
- **Lead sponsor:** Catharina Ziekenhuis Eindhoven
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-27
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-01-01
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06003998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06003998, "Intraperitoneal Irinotecan With Concomitant FOLFOX and Bevacizumab". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06003998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*